Transcriptomics and solid tumors: The next frontier in precision cancer medicine.

🤖 Plain-English Summary

Transcriptomics, which encompasses assessments of alternative splicing and alternative polyadenylation, identification of fusion transcripts, explorations of noncoding RNAs, transcript annotation, and discovery of novel transcripts, is a valuable tool for understanding cancer mechanisms and identifying biomarkers. Many issues regarding the complexity of the analysis, its reproducibility and variability, and the interpretation of the results still need to be addressed.

🔑 Key Findings

• Recent advances in high-throughput technologies have enabled large-scale gene expression profiling.
• Importantly, RNA expression profiling of tumor tissue has been successfully used to determine clinically actionable molecular alterations.
• The WINTHER precision medicine clinical trial was the first prospective trial in diverse solid malignancies that assessed both genomics and transcriptomics to match treatments to specific molecular alterations.

🔗 Related Resources